NCT07187544View on ClinicalTrials.gov

Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery

NARecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Postpartum Hemorrhage (Primary)

Interventions

DRUG

Calcium Chloride

Intravenous calcium chloride 10% (1g) will be administered in 100ml normal saline, over 10 minutes.

OTHER

Placebo

Intravenous administration of 100ml normal saline, over 10 minutes.

DRUG

Carbetocin

50 mcg intravenous carbetocin.

Trial Locations (1)

M5G1X5

RECRUITING

Mount Sinai Hospital, Toronto

All Listed Sponsors

lead

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

OTHER

NCT07187544 - Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery | Biotech Hunter | Biotech Hunter